|
BioCryst Yanks IND on Hep C Drug After FDA Safety Concerns
BioCryst Pharmaceuticals has decided to pull its IND for a new hepatitis C (HCV) drug after the FDA raised concerns about the drug’s toxicity profile. BioCryst already spent more than $4 million developing BCX5191 in the first half of the year and plans to conduct more preclinical studies at lower doses to see if it is still effective in reducing viral load. The company will decide whether to continue development of the antiviral nucleoside based on those results.
Washington Drug Letter |
Register Now
Archives